Aurinia Pharmaceuticals' stock surged 5.20% during Thursday's pre-market session following the release of its fourth-quarter 2025 financial results, which significantly exceeded analyst expectations.

The biopharmaceutical company reported quarterly earnings of $1.53 per diluted share, a massive increase from $0.01 per share a year earlier and well above the consensus estimate of approximately $0.21 to $0.26. Total revenue for the quarter reached $77.1 million, beating estimates and representing a 29% year-over-year increase, driven by strong demand for its lupus nephritis drug LUPKYNIS, whose net product sales grew 29% to $74.2 million.

Furthermore, Aurinia provided optimistic guidance for 2026, projecting total revenue between $315 million and $325 million. The company also highlighted its solid financial position, including a cash balance of $398.0 million and a share repurchase program, alongside progress in its clinical pipeline, including plans to advance studies for its drug candidate aritinercept.